Media - Ironwood Pharmaceuticals

Media

Home
Media

Meredith Kaya

Vice President, Investor Relations and Corporate Communications

617.374.5082

mkaya@ironwoodpharma.com

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

bcalitri@ironwoodpharma.com

Sort by Year

September 29, 2020

Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment

September 2, 2020

Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences

August 6, 2020

Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million

July 23, 2020

Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call

July 21, 2020

Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD)

May 27, 2020

Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D)

May 6, 2020

Ironwood Pharmaceuticals Reports First Quarter 2020 Results and Provides Update on Impact of COVID-19 Pandemic

April 28, 2020

Ironwood and Allergan Receive Notices of Allowance for Patent Applications Covering 72 mcg Dose of LINZESS® (linaclotide)

April 16, 2020

Ironwood Pharmaceuticals to Host First Quarter 2020 Investor Update Call

March 26, 2020

Ironwood Pharmaceuticals Provides Update on Impact of COVID-19

March 14, 2020

A message to our healthcare providers, patients and other partners during COVID-19

February 26, 2020

Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology

February 25, 2020

Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences

February 19, 2020

Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

February 13, 2020

Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance

Copyright © 2020, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.